Skip Navigation

Rheumatology podcast

Rheumatology provides free podcast interviews with experts in the field, keeping you up to date with the latest research on your computer or on the go.

Download Individual Episodes

To browse and listen to any episode from the archive, click here.

Subscribe to the Rheumatology Podcast

To automatically receive new episodes of the Rheumatology podcast, select one of the options below:

If you are having problems subscribing or listening please visit our Podcast Page.

Videos

'The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.’

‘Impact of biologic therapy on functional status in patients with rheumatoid arthritis.’

Rheumatology Podcast Archive

2014
Vasculitis associated with RA - July 2014
Change at the top - February 2014
Treatment for antiphospholipid antibodies - January 2014
The evolution of RA treatment: Will we find the cure? - January 2014
2013
A new kidney-specific diagnostic marker to assess disease activity in lupus nephritis - Dec 2013
Managing patients with early RA - July 2013
Systemic sclerosis: subsets and diagnosis - July 2013
New molecules for the treatment of rheumatoid arthritis - July 2013
Epigenetics and autoimmune disease - July 2013
Frequency of anti-infliximab antibodies: patients with RA in routine care - May 2013
Uric acid-lowering therapy: treatment of gout - April 2013
2012
Role of patients in the management of RA - Dec 2012
Cardiovascular risk in ankylosing spondylitis - December 2012
MRI of joints in children - November 2012
Keeping pace with changes in vasculitis- August 2012
Physical activity in RA patients- June 2012
Evidence for use of complementary medicine in RA- June 2012
Ultrasound guided steroid injections in children- May 2012
Psoriatic arthritis and a placebo controlled RCT- April 2012
ANCA-associated vasculitis- March 2012
BSR and BHPR guidelines on the use of rituximab- Feb 2012
2011
Inflammatory myopathies- June 2011
Early Rheumatoid Arthritis treatment strategies- June 2011
Patient perceptions- June 2011
Cohorts in rheumatoid arthritis- May 2011
50th Anniversary: A perspective on the past- March 2011
Registries- January 2011
2010
Is rheumatoid arthritis a genetically distinct subset?- September 2010
Factors predictive of thrombotic events in SLE patients- August 2010
Spondyloarthropathies- July 2010
Increase in ferritin levels and interstitial lung disease in dermatomyositis- May 2010
Cost of using TNF-alpha inhibitors - April 2010
Cardiovascular disease and rheumatoid arthritis: what is the link? - March 2010
Hypermobility in children - February 2010
The role of biomarkers in the treatment of rheumatoid arthritis - January 2010
2009
Rheumatoid arthritis in elderly patients – December 2009
Active rheumatoid arthritis - November 2009
Systemic Sclerosis- July 2009
Antiphospholipid Antibody Syndrome - June 2009

VASCULITIS ASSOCIATED WITH RA - JULY 2014

Dr Marwan Bukhari, The University Hospitals of Morecambe Bay NHS Foundation Trust, and Dr James Galloway, King’s College London, review a paper by Ashima Makol et al. that evaluates risk factors and clinical outcomes of vasculitis associated with rheumatoid arthritis. They discuss some surprising predictors of the co-morbidity and the limitations of this study, and suggest possible targets for future research.

To listen to the podcast, click below:

Vasculitis associated with RA

Click on the following link to read the related paper for free:

Vasculitis associated with rheumatoid arthritis: a case–control study.

CHANGE AT THE TOP - FEBRUARY 2014

Professor Robert Moots and Professor Jaap van Laar (University Medical Cente Utrecht, Netherlands) discuss Professor Moots’ time as Editor, his achievements over the past 5 years and the changes that have occurred in the publishing industry. This is Professor Moots’ last podcast in charge of the Journal as he hands over the reins of Rheumatology to Professor Jaap van Laar as the new Editor of the Journal.

To listen to the podcast, click below:

Change at the top

TREATMENT FOR ANTIPHOSPHOLIPID ANTIBODIES - JANUARY 2014

Professor Robert Moots and Dr Chris Edwards (Southampton General Hospital, UK) discuss antiphospholipid antibody syndrome and the problems encountered with this disorder. They examine a paper by Maria J. Cuadrado et al on the efficacy and safety of low-dose aspirin in patients positive for antiphospholipid antibodies, discussing the problems of treatment and how the study translates for everyday practice.

To listen to the podcast, click below:

Treatment for antiphospholipid antibodies

Click on the following link to read the related paper for free:

Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).

THE EVOLUTION OF RA TREATMENT: WILL WE FIND THE CURE? - JAN 2014

Professor Robert Moots, Professor Josef Smolen, University of Vienna, Austria, and Professor Emilio Martín-Mola, Hospital Universitario La Paz, Madrid, Spain, praise the advances in treatment of RA over the past thirty years and debate how best to translate these advances into clinical practice to address the unmet needs within the field.

To listen to the podcast, click below:

The evolution of RA treatment: Will we find the cure?

A NEW KIDNEY-SPECIFIC DIAGNOSTIC MARKER TO ASSESS DISEASE... - DEC 2013

Professor Robert Moots and Professor Bernard Lauwerys, Université catholique de Louvain, Brussels, discuss the complex nature of kidney disease in lupus nephritis as well as current and new diagnostic markers used to assess disease activity. They review a paper by Masanori Hanaoka et al that evaluates the use of urinary free light chains as a non-invasive kidney-specific biomarker for the response to treatment of lupus nephritis, and the potential association between the intensity of plasma cell infiltration of the kidney and urinary free light chain levels in the disease. They discuss the key findings as well as the limitations of this exploratory study.

To listen to the podcast, click below:

A new kidney-specific diagnostic marker to assess disease activity in lupus nephritis

Click on the following link to read the related paper for free:

Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis

MANAGING PATIENTS WITH EARLY RA - JULY 2013

Professor Robert Moots and Professor Zhanguo Li (People's Hospital, University of Beijing) discuss the challenges of managing patients with early rheumatoid arthritis and the new classification criteria. They discuss a paper by Krabben et al. on the risk of rheumatoid arthritis developments in patients with unclassified arthritis, debating the limitations of the study and the best way to treat patients.

To listen to the podcast, click below:

Managing patients with early RA

Click on the following link to read the related paper for free:

Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis

SYSTEMIC SCLEROSIS: SUBSETS AND DIAGNOSIS - JULY 2013

Professor Robert Moots and Professor Marco Matucci Cerinic (University of Florence, Florence, Italy) discuss systemic sclerosis providing an overview of the disease and the different subsets. They review a paper by Gonçalves Marangoni et al and discuss the importance of early diagnosis of systemic sclerosis sine scleroderma.

To listen to the podcast, click below:

Systemic sclerosis: subsets and diagnosis

Click on the following link to read the related paper for free:

Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort

NEW MOLECULES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - JULY 2013

Professor Robert Moots talks to Rheumatology co-Editor Roy Fleischmann (clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas, USA) about the future of RA treatment. They discuss the review series on new molecules for the treatment of RA and ruminate on the next big development for RA treatment.

To listen to the podcast, click below:

New molecules for the treatment of rheumatoid arthritis

To read the editorial for the new molecules series for free click the following link:

Back to the future: oral small molecule kinases

The review articles for the series can be found here:

V Kelly and M Genovese. Novel small molecule therapeutics in rheumatoid arthritis
E Feist and G R. Burmester. Small molecules targeting JAKs—a new approach in the treatment of rheumatoid arthritis
J S Nijjar, A Tindell, I B McInnes & S Siebert. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis

EPIGENETICS AND AUTOIMMUNE DISEASE - JULY 2013

Professor Robert Moots and Dr Esteban Ballestar (Bellvitge Biomedical Research Institute [IDIBELL], Barcelona, Spain) discuss epigenetics and this field’s importance for autoimmune diseases. They review a paper by Cheng et al on decoy receptor 3‘s effect on RANK ligand-induced osteoclastogenesis. They discuss potential future developments and the limitations of the study.

To listen to the podcast, click below:

Epigenetics and autoimmune disease

Click on the following link to read the related paper for free:

Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis

FREQUENCY OF ANTI-INFLIXIMAB ANTIBODIES... - MAY 2013

Professor Robert Moots and Dr Steven Young (University of Birmingham School of Immunity and Infection), discuss the therapeutic role of antibodies given directly to patients and their response to these antibodies. They review a paper by Krentil et al. that reports the frequency of anti-infliximab antibodies in patients with RA, the associations with adverse drug reactions and treatment failure and the potential impact of the results of this study. They discuss why patients who initially respond well to TNF inhibitors may not do later, how this new protein chip process might help reduce cost of treatment and anxiety for patients, and whether this process could be applied to other biologic drugs.

To listen to the podcast, click below:

Frequency of anti-infliximab antibodies: patients with RA in routine care

Click on the following link to read the related paper for free:

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure

URIC ACID-LOWERING THERAPY: TREATMENT OF GOUT- APRIL 2013

Professor Robert Moots and Professor Pascal Richette from Lariboisière Hospital in France, discuss urate lowering therapy for the treatment of gout highlighting the issues that are encountered. They review a paper by Mitha et al on the use of rilonacept for gout flare preventionduring initiation of uric acid-lowering therapy with allopurinaol.

To listen to the podcast, click below:

Uric acid-lowering therapy: treatment of gout

Click on the following link to read the related paper for free:

Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial

ROLE OF PATIENTS IN THE MANAGEMENT OF RA - DEC 2012

Professor Robert Moots and Professor Nemanja Damjanov, the Head of Institute of Rheumatology in Belgrade, discuss the role of patients in the management of RA and the implications this has for their treatment. They review a paper by Dougados et al on doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis. They discuss the key points and interesting outcomes of this paper as well as its limitations.

To listen to the podcast, click below:

Role of patients in the management of RA

Click on the following link to read the related paper for free:

Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study

CARDIOVASCULAR RISK IN ANKYLOSING SPONDYLITIS- DEC 2012

Professor Robert Moots and Professor Lai-Shan Tam from the Chinese University of Hong Kong, an expert in ankylosing spondylitis, discuss the risks for co-morbidities, highlighting cardiovascular disease, in ankylosing spondylitis and the potential mechanisms for such risks. They review a paper by Mathieu et al on arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment, speculating on the outcome of the study and its limitations as well as giving advice for clinicians treating ankylosing spondylitis patients.

To listen to the podcast, click below:

Cardiovascular risk in ankylosing spondylitis

Click on the following link to read the related paper for free:

No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months

MRI OF JOINTS IN CHILDREN - NOVEMBER 2012

Professor Robert Moots and Professor Helen Foster, University of Newcastle, discuss the difference of assessing children’s joints compared to adults and the challenges this present. They feature a paper by Von Kalle et al on contrast-enhanced MRI of normal temporomandibular joints in children, discussing the potentials and limitations of this study. What are the implications of this study to how MRIs are interpreted? Listen to the podcast and read the paper to find out more.

To listen to the podcast, click below:

MRI of joints in children

Click on the following link to read the related paper for free:

Contrast-enhanced MRI of normal temporomandibular joints in children—is there enhancement or not?

KEEPING PACE WITH CHANGES IN VASCULITIS- AUGUST 2012

Professor R J Moots and Dr Richard Watts, previous editor of Rheumatology, discuss the major changes taking place in vasculitis, including the improved prognosis, and especially why stratifying patients is important. They examine whether the treatment approach for the different types of vasculitis should be the same – but what is the evidence? Does the aetiology differ for vasculitis in different populations? What are the challenges of splitting this group of diseases? Listen to the podcast for an understanding about the changes in the vasculitis community.

To listen to the podcast, click below:

Keeping pace with changes in vasculitis

Click on the following link to read the related paper for free:

ANCA vasculitis: to lump or split?: Why we should study MPA and GPA separately

PHYSICAL ACTIVITY IN RA PATIENTS- JUNE 2012

Professor Robert Moots and Professor George Kitas, Dudley Group of Hospitals NHS Trust, discuss concerns in treating rheumatoid arthritis patients, focusing on physical activity. They look into the key findings of a paper on the physical activity and energy expenditure in rheumatoid arthritis patients by Henchoz et al. How does rheumatoid arthritis patients’ activity compare to controls, can physical activity benefit these patients?

To listen to the podcast, click below:

Physical activity in RA patients

Click on the following link to read the related paper for free:

Physical activity and energy expenditure in rheumatoid arthritis patients and matched controls

EVIDENCE FOR USE OF COMPLEMENTARY MEDICINE IN RA- JUNE 2012

Professor R Moots and Dr Marwan Bukhari, the Journal’s associate Editor as well as a consultant rheumatologist at Lancaster UK discuss about advising patients regarding alternative treatments or complementary therapy. They review the evidence from a paper published online in Rheumatology by Macfarlane et al. on a systematic review about the effectiveness of complementary therapy in the management of RA. What can a practicing clinician infer from this review and what should he or she advise their patient based on this review? To find out more, listen to the podcast.

To listen to the podcast, click below:

Evidence for use of complementary medicine in RA

Click on the following link to read the related paper for free:

A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: rheumatoid arthritis

ULTRASOUND GUIDED STEROID INJECTIONS IN CHILDREN- MAY 2012

Professor Robert Moots and Dr Athimalaipet Ramanan from the Bristol Royal Hospital for Children, discuss the challenges of treating children with rheumatic diseases, focusing on joint injections. They feature Dr Ramanan’s paper on ultrasound guided steroid injections into temporomandibular joints in children with active JIA. They discuss the outcomes of the study and its limitations. Is ultrasound necessary to ensure patients are injected in the right place? Listen to the podcast and read the paper and make up your own mind.

To listen to the podcast, click below:

Ultrasound guided injections in children

Click on the following link to read the related paper for free:

Safety and efficacy of US-guided CS injection into temporomandibular joints in children with active JIA

PSORIATIC ARTHRITIS AND A PLACEBO CONTROLLED RCT- APRIL 2012

Methotrexate in psoriatic arthritis - does it really work or are we just giving a placebo? Listen to Professor Robert Moots and Dr Robert Thompson, University of Liverpool discuss the management psoriatic arthritis and analyse a major new randomized placebo-controlled trial of MTX in PsA article recently published by G Kingsley et al. Will this change your practice?

To listen to the podcast, click below:

Psoriatic arthritis and a placebo controlled RCT

Click on the following link to read the related paper for free:

A randomized placebo-controlled trial of MTX in PsA

ANCA-ASSOCIATED VASCULITIS- MARCH 2012

Professor Robert Moots and Dr Alfred Mahr discuss the challenges of ANCA-associated vasculitis, use of cyclophosphamide and granulomotosis with angiitis. They also discuss the use of rituximab particularly in light of the recommendations published by Guerry et al., how strong is the evidence base for these recommendations and how do these recommendations differ from Dr Mahr’s practice?

To listen to the podcast, click below:

ANCA-associated vasculitis

Click on the following link to read the related paper for free:

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis

BSR AND BHPR GUIDELINES ON THE USE OF RITUXIMAB- FEB 2012

How do you manage refractory rheumatoid arthritis? Listen to Professor Robert Moots, Editor, and Professor Paul Peter Tak from the University of Amsterdam, discuss advances in the treatment of RA and consider differences between clinical trials and real life clinical work. They also debate important new guidelines for the use of the rituximab in rheumatoid arthritis published in the Journal.

What is your view on this? Listen to the Podcast, look up the paper and make up your own mind.

To listen to the podcast click below:

Use of rituximab

Click on the following link to read the related paper for free:

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis

INFLAMMATORY MYOPATHIES- JUNE 2011

Professor Robert Moots and Dr Piet van Riel discuss the treatment of inflammatory myopathies and their efficacies in patients. They talk about a paper, on which Dr van Riel is a co-author, investigating the use of rituximab to treat refractory inflammatory myopathies. They look into the reasons behind the study and give advice for people looking after patients with inflammatory myopathies.

To listen to the podcast click below:

Inflammatory myopathies

Click on the following link to read the related paper for free:

Rituximab treatment in patients with refractory inflammatory myopathies

EARLY RHEUMATOID ARTHRITIS TREATMENT STRATEGIES- JUNE 2011

Professor Robert Moots and Professor Janet Pope talk about treatment strategies for early rheumatoid arthritis and the influence cost-effectiveness has. To further highlight the issues they discuss a paper by Schipper et al. comparing the cost-effectiveness of 3 different treatment strategies for patients with early RA.

To listen to the podcast click below:

Treatment strategies

Click on the following link to read the related paper for free:

Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective

PATIENT PERCEPTIONS- JUNE 2011

Professor Robert Moots talks to Dr Fernando Cavalcanti about inflammatory arthritis and its treatment in Brazil, highlighting cultural differences in disease management and between patient and Doctor perceptions. They also discuss a review by Verschueren and Westhovens on the challenges of putting scientific treatment into clinical practice.

To listen to the podcast click below:

Patient perceptions

Click on the following link to read the related paper for free:

Optimal care for early RA patients: the challenge of translating scientific data into clinical practice

COHORTS IN RHEUMATOID ARTHRITIS- MAY 2011

Professor Robert Moots and Professor Nancy Lane discuss a paper by Liao et al. about a rheumatoid arthritis cohort in Boston, USA. They talk about the use and importance of such cohorts and how they can inform treatment strategies and practices. They look into the strengths, limitations and challenges for linking bed-side observations to laboratory developments.

To listen to the podcast click below:

Rheumatoid arthritis cohorts

Click on the following link to read the related paper for free:

Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study

50TH ANNIVERSARY: A PERSPECTIVE ON THE PAST- MARCH 2011

As part of the Journal’s 50th Anniversary celebrations Professor Robert Moots talks to Professor David GI Scott and Dr Michael Snaith about how the rheumatology field has changed over the past 60 years. They discuss treatment, therapeutic and practice developments and how a greater understanding of musculoskeletal disease has shaped these advancements.

To listen to the podcast click below:

A perspective on the past

To find out more information regarding the Journal’s 50th celebrations please click here.

REGISTRIES- JANUARY 2011

Professor Robert Moots and Professor David Isenberg discuss registries, what they are, their aims and outcomes. They highlight the British Society for Rheumatology Biologics Register, the largest biologics register in the world, detailing its design, aims and findings. Professor David Isenberg has been a guest Editor on the Journal’s themed issue on registries, a collection of papers on this topic.

To listen to the podcast click below:

Registries

To read the Journal’s themed issue on Registries in Rheumatological and Musculoskeletal Conditions please click here.

IS RA A GENETICALLY DISTINCT SUBSET?- SEPTEMBER 2010

Is rheumatoid arthritis a single disease or a group of related diseases? Professor Robert Moots and Professor Anthony Russell discuss this issue, probing into a paper by Ohmura et al. published in Rheumatology. They discuss the key developments of this paper, what it means for treatment and its potential limitations.

To listen to the podcast click below:

Is rheumatoid arthritis a genetically distinct subset?

Click on the following link to read the related paper for free:

Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis.

THROMBOTIC EVENTS IN SLE PATIENTS- AUGUST 2010

The Editor Professor Robert Moots and Professor Mohammed Tikly, who is from the University of the Witwatersrand in South Africa, discuss a paper by Burgos et al. about the complications of thrombic events in systemic lupus and the implications of this for clinical practice.

To listen to the podcast click below:

Factors predictive of thrombotic events in SLE patients

Click on the following link to read the related paper for free:

Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients.

SPONDYLOARTHROPATHIES- JULY 2010

In this podcast Professor Robert Moots and Dr Dirk Elewaut discuss spondyloarthropathy diseases and their manifestations. They then go on to discuss a paper by Bruan et al. recently published in Rheumatology on the clinical manifestations of ankylosing spondylitis with and without concomitant psoriasis. They discuss the key issues the paper investigates and the study’s limitations.

To listen to the podcast click below:

Spondyloarthropathies: Ankylosing spondylitis with and without concomitant psoriasis - July 2010

Click on the following link to read the related paper for free:

Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis

FERRITIN LEVELS AND ILD IN DERMATOMYOSITIS- MAY 2010

Can measurement of serum ferritin predict the development and severity of acute interstitial lung disease in dematomyositis? Professors Moots and Panayi delve into the paper by Gono et al who propose that the acute phase protein, ferritin, may represent a biomarker for complications in dermatomyositis.

To listen to their discussion about this study, issues the paper addressed and its limitations, please click link below.

Increase in ferritin levels and interstitial lung disease in dermatomyositis

Click on the following link to read the related paper for free:

Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis

COST OF USING TNF-ALPHA INHIBITORS - APRIL 2010

What is the cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis?. This paper, set in Finland, by Hallinen et al. is discussed by Professor Robert Moots and Dr. Ronald Frits van Vollenhoven. In the Podcast, they discuss current use of biologics, the effectiveness of TNF inhibitors, DMARDs and rituximab and consider whether the economic model used in this paper can effectively determine relative cost-effectiveness in a clinical setting.

Click on the link below to listen to this interview:

Cost of using TNF-alpha inhibitors

Click on the following link to read the related paper for free:

What is the cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis?

CARDIOVASCULAR DISEASE AND RHEUMATOID ARTHRITIS - MARCH 2010

An MRI study about understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation by Puntmann et al. is the paper for the discussion between Professor Robert Moots and Dr Christopher Edwards. Is there a link between cardiovascular diseases and RA, how does this association affect patients with RA and questions about this study are answered in this podcast.

Click on the link below to listen to this interview:

Cardiovascular disease and rheumatoid arthritis: what is the link?

Click on the following link to read the related paper for free:

An MRI study about understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation

HYPERMOBILITY IN CHILDREN - FEBRUARY 2010

A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility by Sue et al. published in Rheumatology is discussed by Robert Moots and Michael Beresford. What is childhood hypermobility and how does it present? Answers to these questions and discussions about the trial form the basis for this podcast.

Click on the link below to listen to this interview:

Hypermobility in children

Click on the following link to read the related paper for free:

A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility

TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOMARKERS- JAN 2010

Robert Moots and Stephen Hall discuss the challenges in identifying biomarkers for selecting treatment and predicting adverse events in rheumatoid arthritis. They then discuss a paper by Quartuccio et al. investigating the utility of rheumatoid factor, anti-CCP antibodies and response to TNFi as potential predictors of response to rituximab in rheumatoid arthritis.

Click on the link below to listen to this interview:

The role of biomarkers in the treatment of rheumatoid arthritis

Click on the following link to read the related paper for free:

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

RHEUMATOID ARTHRITIS IN ELDERLY PATIENTS- DECEMBER 2009

Is rheumatoid arthritis a homogeneous disease and can it be categorized by age? In our next podcast, Robert Moots with Daniel Solomon discusses not only these questions but also a study recently published by Rheumatology by Marcus Köller et al about the response of methotrexate or TNF inhibitors in elderly patients.

Click on the link below to listen to this interview:

Rheumatoid arthritis in elderly patients

Click on the following link to read the related paper for free:

Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients

ACTIVE RHEUMATOID ARTHRITIS - NOVEMBER 2009

In this podcast, Robert Moots and Roy Fleischmann discuss aspects of rheumatoid arthritis and concerns that patients commonly have about the disease. They then discuss a paper published in the Journal by Aslam Anis et al. about the COMET study that examined the effect of etanercept on work productivity in patients with active rheumatoid arthritis.

Click on the link below to listen to this interview:

Active rheumatoid arthritis

Click on the following link to read the related paper for free:

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study

SYSTEMIC SCLEROSIS- JULY 2009

Pulmonary complications of systemic sclerosis are amongst the most challenging to manage. In this podcast, Ulf Mueller-Ladner discusses the current management of these complications with Robert Moots and the potential for a new, more effective therapy using rituximab - in an article (Daoussis et al) recently published in Rheumatology

Click on the link below to listen to this interview:

Systemic Sclerosis

Click on the following link to read the related paper for free:

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

ANTIPHOSPHOLIPID ANTIBODY SYNDROME - JUNE 2009

In this first podcast from Rheumatology, Munther Khamashta (St Thomas’ Hospital London) and Anisur Rahman (University College London) discuss aspects of treatment of antiphospholipid antibody syndrome (APS) today and the potential for future therapy, in the context of recent advances in understanding the pathological processes that underlie this disease.

The papers discussed in this podcast are available to read for free here:

1. Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies (Mecacci et al)
2. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? (Ames et al)

Click on the link below to listen to this interview:

Antiphospholipid Antibody Syndrome